Insights

On-demand webinar: Semaglutides weight loss drugs

Insight Article 27 March 2025 27 March 2025
North America, UK & Europe
Regulatory movement
Insurance

Semaglutides are diabetes control drugs, which work by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite. In 2021, they began to be marketed for the treatment of obesity.

With brands such as Ozempic becoming household names, Semaglutides are an emerging risk in its early stages, as trials are still underway to determine the full extent of the associated side effects. Given recent precedents in pharmaceutical liability, however, the MDL (Multidistrict litigation) is worth watching closely.

This episode explores the potential risks and lawsuits surrounding Semaglutides, including their side effects and possible implications for insurers.

Watch the recording

End